DNLI

Denali Therapeutics Inc.

Contracts

Total Value

Stock Metrics

12.1%

Short % Float

12.1d to cover · Moderate squeeze

1.0%

Inst % Float

10 holders · 2026-06-30

T. Rowe Price Inve

Top Holder

10.1% of float

144.3M sh

Public Float

27/100

Dilution Score

Medium

27 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

27/100

MEDIUM

Inst: 1.01% · Top: T. Rowe Price Investment Management, Inc.

Biotech Analytics

Neuroscience

56.62

Squeeze risk: MODERATE

Insider Buying0

Publications100

Dilution Risk27

Clinical Trials100

Short Interest50